1,8-二氮杂螺[5.5]十一烷-1-甲酸叔丁酯 | 960294-18-2

• 物质功能分类: 有机原料 - 螺环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 1,8-二氮杂螺[5.5]十一烷-1-甲酸叔丁酯
• 中文别名: 1,8-二氮杂螺[5.5]十一烷-1-羧酸1,1-二甲基乙基酯；1,8-二氮杂螺[5.5]十一烷-1-羧酸叔丁酯
• 英文名称: Tert-butyl 1,8-diazaspiro[5.5]undecane-1-carboxylate
• CAS: 960294-18-2
• 化学式: C₁₄H₂₆N₂O₂
• 分子量: 254.37
• InChiKey: VPLODDZAJNYXTC-UHFFFAOYSA-N

物化性质

• 沸点：
  354℃
• 密度：
  1.05
• 闪点：
  168℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(bromomethyl)-3-chloro-N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-5-(trifluoromethyl)benzamide 、 1,8-二氮杂螺[5.5]十一烷-1-甲酸叔丁酯 生成 3-chloro-N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-4-(1,8-diazaspiro[5.5]undecan-8-ylmethyl)-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  BENZAMIDE DERIVATIVE

  摘要：

  本发明涉及由公式(I)表示的苯甲酰胺衍生物或其药学上可接受的盐。

  公开号：

  US20150152047A1

文献信息

• [EN] PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS PYRROLO[2,3-B]PYRIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2019034890A1

  公开（公告）日：2019-02-21

  The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

  本申请涉及公式I的化合物，或其盐、水合物或溶剂合物，如本文所定义。发现这些化合物具有药理效应，特别是在MRCK上。还提供包含这些化合物的药物组合物。本发明还涉及将这些化合物用作治疗剂，特别是用于治疗和/或预防增殖性疾病，如癌症。
• [EN] AZACARBAZOLE BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK AZACARBAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016164284A1

  公开（公告）日：2016-10-13

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set forth herein. The present invention also provides pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

  本发明提供了根据式（I）提供的Bruton's酪氨酸激酶（Btk）抑制剂化合物，或其药学上可接受的盐，其中CH、R1、R1a、R1b、R2、R3以及下标m1、m2、p、q和t如本文所述。本发明还提供了包括这些化合物的药物组合物以及它们在治疗中的应用。具体而言，本发明涉及使用式（I）的Btk抑制剂化合物治疗Btk介导的疾病。
• [EN] INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS DE PEPTIDYLARGININE DÉIMINASES
  申请人：GILEAD SCIENCES INC

  公开号：WO2022140390A1

  公开（公告）日：2022-06-30

  The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

  本公开涉及用于治疗与肽基精氨酸脱亚胺酶（PADs）相关的疾病（例如肽基精氨酸脱亚胺酶4型（PAD4））的新化合物。本公开还涉及用于制备这些化合物的过程和中间体，使用这些化合物的方法以及包含所述化合物的制药组合物。
• Benzimidazole derivatives and their uses
  申请人：TEIJIN PHARMA LIMITED

  公开号：US11332459B2

  公开（公告）日：2022-05-17

  The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明涉及瞬时受体电位通道 6（TRPC6）蛋白活性的抑制剂。本发明提供了式(I)化合物或其药学上可接受的盐、包含本发明化合物的药物组合物、制造本发明化合物的方法及其治疗用途。
• Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
  申请人：Cancer Research Technology Limited

  公开号：US11447505B1

  公开（公告）日：2022-09-20

  The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

  本申请涉及如本文所定义的式 I 化合物或其盐、水合物或溶液。发现本化合物具有药理作用，特别是在 MRCK 方面。本发明还提供了包含上述化合物的药物组合物。本发明还涉及将这些化合物用作治疗剂，特别是用于治疗和/或预防癌症等增殖性疾病。